Objective. Systemic lupus erythematosus (SLE) is a multi-system inflammatory disease characterized by production of various autoantibodies. The aim of this study was to investigate the presence of anti-ficolin-2 antibodies in SLE patients and to evaluate the association between the levels of these autoantibodies, clinical manifestations, and disease activity.
Introduction
Systemic lupus erythematosus (SLE) is a multi-system inflammatory disease presenting a broad spectrum of clinical manifestations affecting numerous organs (heart, kidney, brain, blood vessels). The course of the disease is unpredictable, with flares alternating with remissions, thus making the monitoring of patients particularly difficult, especially regarding possible life threatening organ involvement. SLE is a prototypical autoimmune disease characterized by T and B lymphocyte dysfunction and production of various autoantibodies.
Although the mechanisms of induction of autoantibodies are complex and not fully deciphered, a contribution of defects in apoptotic cell clearance leading to secondary cell necrosis and subsequent release of intracellular autoantigens has been proposed (1) . In accordance with this hypothesis, molecules involved in the uptake of dying cells, such as complement recognition proteins, could play a role in the prevention of autoimmune pathologies such as SLE. These proteins include ficolin-2, a member of the complement
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Ficolin-2 is an oligomeric protein composed of 35 kDa subunits assembled in triple helix, consisting of both collagen-like and fibrinogen-like domains. This protein is produced by hepatocytes with a median plasma concentration level of 5.4 µg/mL in healthy humans (4) . Ficolin-2 plays an important role in innate immunity and the maintenance of tissue homeostasis, thanks to its capacity to bind specific pathogen-and apoptotic cells-associated molecular patterns. Target recognition triggers the innate immune response by either activating the lectin complement pathway or binding to collectin cellular receptors.
Interestingly the serum levels of ficolin-2 in Japanese SLE patients were found lower than those in healthy individuals, but were not associated with disease activity (5) . Two recent studies reported the association of low ficolin-2 plasma levels, more precisely with lupus nephritis (LN) (6,7). However ficolin-2 measurement has been shown to be strongly dependent on experimental variations and blood sample handling procedures, rendering the correlation with clinical features questionable in the absence of standardized measurement (8) . In addition, a genetic study reported the association of ficolin-2 gene polymorphisms with nephritis in SLE patients (9) .
Antibodies against several complement recognition proteins, including C1q, mannosebinding lectin (MBL) and ficolin-3, have been reported to contribute to the development of SLE, supporting the hypothesis that the complement system is deeply involved in the pathogenesis of this disease in multiple ways (10) (11) (12) . To date, no study reported the presence of antibodies targeting ficolin-2 in SLE sera. This study aimed to investigate the presence of anti-ficolin-2 antibodies in SLE patients and to evaluate the association between the presence of these autoantibodies and clinical manifestations, and disease activity. 
This article is protected by copyright. All rights reserved. l'Informatique et des Libertés", CNIL N°2030950vO). The study has also been registered to clinicaltrial.gov (N° NCT03063281). The study was done in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. For SLE patients, clinical and biological manifestations and disease activity, evaluated using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at the time of sampling, were recorded. The SLE patients were divided into two groups for further analyses: a group with "low disease activity" (SLEDAI score ≤ 4, n = 88) and a group with "high disease activity" (SLEDAI score > 4, n = 77), according to the physician in charge. All patients with renal involvement had an active LN, defined by the presence of a significant proteinuria (≥ 0.5 g/day) and/or the presence of hematuria, aseptic leukocyturia or urinary casts, which was documented by renal biopsy and classified according to the ISN/RPS classification. Samples were collected just before kidney biopsy. Active proliferative LN was defined as a class III or IV LN with activity, +/-class V, as opposed to non-proliferative LN (classes I, II or isolated V).
Anti-ficolin-2 antibodies assessment. Recombinant ficolin-2 was produced in Chinese
hamster ovary cells and purified using a one-step affinity chromatography on Nacetylcysteine-Sepharose, as previously described (13) . Detection of anti-ficolin-2 antibodies was adapted from an ELISA previously described for measurement of anti-ficolin-3 antibodies (12). Microtiter plates (96 wells) were coated overnight at 4°C with 4 µg/mL of recombinant ficolin-2 in 15 mM Na 2 CO 3 , 35 mM NaHCO 3 (pH 9.6). The plates were washed three times with Phosphate Buffer Saline (PBS) containing 0.1% Tween-20 (w/v) (PBS-T) and blocked for 1 h at room temperature (RT) with PBS-T containing 1% BSA (w/v). After washing as above, serum samples were added to the wells and incubated overnight at 4°C.
After four washings as above, horseradish peroxidase (HRP)-conjugated goat polyclonal antihuman IgGs (The Binding Site, dilution 1:15000) were added for 1 h at RT. Subsequently tetramethylbenzidine substrate was added to each well, the reaction was stopped by addition of H 2 SO 4 and optical densities (ODs) were measured at 450 nm. The threshold value of 95 AU was calculated using 98 th percentile on OD reading for the control group. A value was considered significantly elevated when the concentration was above 95 AU (arbitrary units).
The concentration was defined as (OD sample/OD control) x 100 AU.
Anti-dsDNA antibodies, complement fractions, anti-C1q and anti-ficolin-3 antibodies assessment. Anti-double stranded (ds)DNA were detected by ELISA (BIORAD) with normal value defined as < 50 IU/mL. Complement levels were measured by nephelometry (BN II,
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Siemens), according to manufacturer's instructions, with normal range for C4 being > 100 mg/l and for C3 > 880 mg/l. Anti-C1q and anti-ficolin-3 antibodies were detected by ELISA, as previously described (12 
Results
Characteristics of SLE patients. Characteristics of the 165 SLE patients, including 36 biopsy-proven active LN, and matched healthy controls are provided in Table 1 . At inclusion, the median SLEDAI score was 4 (range 0-24). 88 patients were classified in the "low disease activity" group and 77 in the "high disease activity" group, as previously defined (see Figure 1) .
Association of anti-ficolin-2 antibodies with lupus activity. SLE patients were divided into two groups: a group with "low disease activity" (SLEDAI score ≤ 4) and a group with "high disease activity" (SLEDAI score > 4), according to the physician in charge. Anti-ficolin-2
antibodies were detected as positive in 34 (44%) of the 77 SLE patients with "high disease activity" and in 26 (30%) of the 88 SLE patients (26/88) with "low activity" Titers of antificolin-2 antibodies were significantly higher in SLE patients with "high disease activity"
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This article is protected by copyright. All rights reserved. Figure 2B ). We previously demonstrated in this cohort of SLE patients that low complement C3 and/or C4, anti-dsDNA, anti-C1q, and anti-ficolin-3 levels were associated with renal disease activity (12) . As in the present study anti-ficolin-2 antibodies were associated with renal disease activity, we then described the diagnostic performances of this biomarker alone and in combination with the other ones.
Sensitivity and specificity of anti-ficolin-2 antibodies for SLE renal involvement were respectively 64% and 68%. Predictive positive and negative values were respectively 64% and 68%. Interestingly, the combination of anti-ficolin-2, anti-ficolin-3 and anti-C1q showed a higher specificity of 95% for renal involvement than without anti-ficolin-2 (Supplementary Table 1 ).
Discussion
Our study is the first one assessing the presence of antibodies targeting ficolin-2 and measuring their titers using ELISA in our cohort of SLE patients. Levels of anti-ficolin-2 autoantibodies were significantly higher compared to healthy subjects. They were found positive in 61/165 (37%) SLE patients. These antibodies were found negative in other autoimmune diseases such as rheumatoid arthritis and Sjögren's syndrome. SLE is characterized by a systemic inflammation involving multiple organs including skin, kidney, joints, heart and brain. Interestingly, whereas a low positive correlation of anti-ficolin-2 antibodies with the SLEDAI score which reflects the disease activity was found, the presence of anti-ficolin-2 antibodies was significantly related to renal involvement. No significant association between the positivity of anti-ficolin-2 antibodies and other SLE clinical outcomes was observed. In line with these findings, we observed a very high prevalence (86%) of anti-ficolin-2 antibodies in the subset of SLE patients with active LN.
Lupus nephritis, one of the most frequent and serious complications in SLE patients, and a major predictor of poor outcome, is a real challenge in the management of SLE. In clinical practice, conventional parameters such as proteinuria, abnormal creatinine and an elevated anti-dsDNA antibody titer concomitant with reduced complement levels (C3, C4)
are disease-activity biomarkers of SLE and LN. However, they still lack sensitivity and specificity for detecting ongoing disease activity in lupus kidneys and early relapse of nephritis (14) . Our results indicate that anti-ficolin-2 antibodies might be an additional parameter to distinguish active LN from active non-renal SLE flare. A significant correlation between anti-ficolin-2 antibodies and other SLE biological biomarkers was found, including anti-dsDNA antibodies, low complement levels, anti-C1q antibodies and also anti-ficolin-3
antibodies, recently reported to be significantly associated with active LN (12) . As the combined measurement of a variety of autoantibodies is expected to be more valuable, all these biomarkers were tested in combination. Interestingly, the combination of anti-ficolin-2,
anti-ficolin-3 and anti-C1q outperformed anti-C1q, anti-dsDNA or low complement alone but also anti-ficolin-3 and anti-C1q in combination, demonstrating a higher specificity (98%) than any other serological biomarker (12) . This combination of anti-C1q, anti-ficolin-3 and 
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